HC
BPMC

Henshaw Capital’s Blueprint Medicines BPMC Stock Holding History

Henshaw Capital’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,066
Closed -$906K – 263
2025
Q2 		$906K Sell
7,066
-1,409
-17% -$146K 0.04% 165
2025
Q1 		$750K Hold
8,475
– – 0.03% 170
2024
Q4 		$739K Hold
8,475
– – 0.03% 153
2024
Q3 		$784K Hold
8,475
– – 0.03% 160
2024
Q2 		$913K Buy
8,475
+134
+2% +$13.4K 0.04% 118
2024
Q1 		$791K Sell
8,341
-1,547
-16% -$133K 0.04% 127
2023
Q4 		$912K Sell
9,888
-223
-2% -$14.4K 0.05% 117
2023
Q3 		$508K Buy
10,111
+3,860
+62% +$206K 0.03% 153
2023
Q2 		$395K Buy
6,251
+602
+11% +$32.7K 0.02% 147
2023
Q1 		$254K Hold
5,649
– – 0.02% 198
2022
Q4 		$247K Buy
5,649
+841
+17% +$40.3K 0.02% 200
2022
Q3 		$317K Hold
4,808
– – 0.02% 196
2022
Q2 		$243K Hold
4,808
– – 0.02% 257
2022
Q1 		$307K Hold
4,808
– – 0.02% 244
2021
Q4 		$515K Hold
4,808
– – 0.03% 169
2021
Q3 		$494K Hold
4,808
– – 0.03% 166
2021
Q2 		$423K Buy
4,808
+1,052
+28% +$96.4K 0.03% 198
2021
Q1 		$365K Buy
3,756
+555
+17% +$55.4K 0.02% 222
2020
Q4 		$359K Buy
3,201
+641
+25% +$67.6K 0.03% 218
2020
Q3 		$237K Buy
+2,560
New +$197K 0.02% 273

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Henshaw Capital's BPMC Position: Q3 2025 in Review

Henshaw Capital sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 7,066 shares — an estimated $906K sold.

Henshaw Capital first reported a position in BPMC in Q3 2020 and held it in 20 quarters. The position peaked at $913K in Q2 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Henshaw Capital reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Henshaw Capital sold 7,066 Blueprint Medicines shares in Q3 2025, an estimated $906K.
  • Henshaw Capital first reported a position in Blueprint Medicines in Q3 2020 and held it in 20 quarters.
  • Henshaw Capital's Blueprint Medicines position peaked at $913K in Q2 2024.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Henshaw Capital's 13F filing for Q3 2025, filed 28 May 2026.